Enzo Biochem Net Profit Margin 2010-2022 | ENZ

Enzo Biochem net profit margin from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Enzo Biochem Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-01-31 $0.12B 0 0.00%
2021-10-31 $0.12B $0.01B 4.31%
2021-07-31 $0.12B $0.01B 5.93%
2021-04-30 $0.11B $0.00B 0.88%
2021-01-31 $0.10B $-0.01B -11.34%
2020-10-31 $0.09B $-0.02B -24.71%
2020-07-31 $0.08B $-0.03B -38.16%
2020-04-30 $0.08B $-0.03B -40.26%
2020-01-31 $0.08B $0.00B 1.25%
2019-10-31 $0.08B $0.00B 1.25%
2019-07-31 $0.08B $0.00B 3.70%
2019-04-30 $0.08B $0.00B 2.41%
2019-01-31 $0.09B $-0.02B -26.14%
2018-10-31 $0.10B $-0.02B -16.84%
2018-07-31 $0.10B $-0.01B -10.89%
2018-04-30 $0.10B $-0.01B -4.85%
2018-01-31 $0.11B $-0.00B -1.90%
2017-10-31 $0.11B $-0.00B -1.90%
2017-07-31 $0.10B $-0.00B -1.92%
2017-04-30 $0.11B $0.03B 32.08%
2017-01-31 $0.11B $0.03B 30.48%
2016-10-31 $0.10B $0.04B 38.46%
2016-07-31 $0.10B $0.05B 43.69%
2016-04-30 $0.10B $0.02B 16.67%
2016-01-31 $0.10B $0.02B 16.00%
2015-10-31 $0.10B $0.01B 5.10%
2015-07-31 $0.10B $-0.00B -3.06%
2015-04-30 $0.10B $-0.01B -14.43%
2015-01-31 $0.10B $-0.01B -11.34%
2014-10-31 $0.10B $-0.01B -11.34%
2014-07-31 $0.10B $-0.01B -10.42%
2014-04-30 $0.09B $-0.01B -10.64%
2014-01-31 $0.09B $-0.02B -17.20%
2013-10-31 $0.09B $-0.02B -19.57%
2013-07-31 $0.09B $-0.02B -20.21%
2013-04-30 $0.10B $-0.04B -44.33%
2013-01-31 $0.10B $-0.04B -40.00%
2012-10-31 $0.10B $-0.04B -36.89%
2012-07-31 $0.10B $-0.04B -36.89%
2012-04-30 $0.10B $-0.02B -14.42%
2012-01-31 $0.10B $-0.01B -13.46%
2011-10-31 $0.10B $-0.02B -15.53%
2011-07-31 $0.10B $-0.01B -12.62%
2011-04-30 $0.10B $-0.02B -14.85%
2011-01-31 $0.10B $-0.02B -18.18%
2010-10-31 $0.10B $-0.02B -22.45%
2010-07-31 $0.10B $-0.02B -23.71%
2010-04-30 $0.10B $-0.02B -22.68%
2010-01-31 $0.10B $-0.02B -21.88%
2009-10-31 $0.09B $-0.02B -20.21%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00